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Abstract: Pregnane X receptor (PXR) has been reported to regulate the expression of  
drug-metabolizing enzymes, such as the cytochrome P450 3A (CYP3A) family and 
transporters, such as multiple drug resistance 1 (MDR1). Fucoxanthin, the major 
carotenoid in brown sea algae, is a putative chemopreventive agent. In this study, we 
determined whether fucoxanthin could overcome drug resistance through attenuation of 
rifampin-induced CYP3A4 and MDR1 gene expression by PXR-mediated pathways in 
HepG2 hepatoma cells. We found that fucoxanthin (1–10 μM) significantly attenuated 
rifampin (20 μM)-induced CYP3A4, MDR1 mRNA and CYP3A4 protein expression at 
24 h of incubation. Mechanistically, fucoxanthin strongly attenuated the PXR-mediated 
CYP3A4 promoter activity in HepG2 cells. In addition, fucoxanthin attenuated constitutive 
androstane receptor (CAR)- and rPXR-mediated CYP3A4 promoter activity in this cell 
line. Using the mammalian two-hybrid assay, we found that fucoxanthin significantly 
decreased the interaction between PXR and SRC-1, a PXR co-activator. Thus, fucoxanthin 
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can decrease rifampin-induced CYP3A4 and MDR1 expression through attenuation of 
PXR-mediated CYP3A4 promoter activation and interaction between PXR and co-activator. 
These findings could lead to potentially important new therapeutic and dietary approaches 
to reduce the frequency of adverse drug reactions.  
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1. Introduction 
Fucoxanthin, the major non-provitamin A carotenoid found in Undaria Pinnatifida, has been  
shown to have many biological functions, such as suppression of adipocyte differentiation [1],  
anti-mutagenicity [2], anti-inflammation [3], and anti-cancer effects. Studies have shown that 
fucoxanthin exhibits anti-proliferative potential by inducing cell cycle arrest at the G0/G1 phase and 
apoptosis of various cell lines, such as prostate cancer PC-3, DU 145, and LNCaP cells [4], leukemia 
HL-60 cells [5], colon cancer HT-29, Caco-2, and DLD-1 cells [6]. Fucoxanthin can be hydrolyzed 
into fucoxanthinol by lipase, cholesterol esterase, carboxylesterase in intestinal Caco-2 cells and in 
mice [7] then subsequently converted into amarouciaxanthin a, which is a major metabolite of 
fucoxanthin in the liver of mice [8]. Moreover, Hashimoto et al. reported that fucoxanthinol is 
detectable at 44.2 nmol/L in human plasma in subjects orally administered with kombu extract 
containing 31 mg fucoxanthin for 24 h [9]. 
A lot of evidence indicates that phytochemicals found in fruit and vegetables exhibit chemoprevention 
and anti-drug resistance potential. For example, curcumin [10], epigallocatechin-3-gallate (EGCG) [11] 
and resveratrol [12] and its analogues [13], are useful in overcoming drug resistance in cancer. In 
addition, some carotenoids such as lycopene, zeaxanthin, and capsanthin have been shown to decrease 
drug resistance in human MDR1-transfected mouse lymphoma cells and human breast cancer cells, 
indicating that carotenoids are possible resistance modifiers in cancer chemotherapy [14]. However, it 
is unclear whether fucoxanthin itself is capable of overcoming drug resistance. 
The cytochrome P450 (CYP) families are superfamily of hemethiolate-containing proteins, which 
metabolize a number of endogenous substrates such as steroids, eicosanoids, and xenobiotics including 
various carcinogens, toxins, and therapeutic drugs. CYP3A4 makes up the largest portion of the CYP 
family, which is mainly distributed in the liver and intestine and has clinical importance because it 
metabolizes at least 50% of marketed pharmaceutical agents [15]. Both expression and activity of 
CYP3A4 are also greatly regulated by many drugs and dietary chemicals, such as rifampin  
(an antibiotic), carbamazepine (an anticonvulsant), glucocorticoids, and hyperforin (a major component 
of St. John’s wort) [16]. In addition, the MDR1 gene encodes P-glycoprotein (P-gp), which is a 
multidrug transporter that has a major role in drug resistance [17]. MDR1 has been found to promote 
the efflux of a wide range of structurally and functionally diverse compounds from cells, which 
decrease their intracellular accumulations [18,19]. The effectiveness of chemotherapy is often limited 
by drug resistance, and much effort has been expended to determine an approach to overcome this 
resistance [20]. 
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Human pregnane X receptor (PXR), a member of the nuclear receptors (NRs) superfamily encoded  
by NR1I2, has been shown to be involved in protecting tissues from potentially toxic, exogenous and 
endogenous compounds, in drug metabolism, bile acid transport, biotransformation and clearance of 
widely used anticancer drugs as well as modulating the inflammatory response mediated by exogenous 
toxins [21–23]. Being a ligand-activated transcription factor, the PXR pathway is also activated by a 
large number of prescription drugs designed to treat infection, cancer, convulsion, and hypertension, and 
thus it is believed to play an important role in drug metabolism/efflux and drug-drug interactions [24]. 
Indeed, PXR activation has been shown to have an anti-apoptotic role in colon cancer cells [25] and 
induces FGF19-dependent tumor aggressiveness in humans and mice [26], whereas PXR antagonist 
decreased cell proliferation in breast cancer [27] and interfered with cancer drug resistance [28]. The 
activation of PXR can stimulate the expression of many important drug metabolism enzymes (DMEs) 
and ATP binding cassette (ABC) efflux transporters, which are able to prevent the intracellular 
accumulation of drugs by increasing excretion or efflux mechanisms [17]. Thus, PXR functions as a 
xenobiotic sensor [29] to coordinate and regulate drug clearance in the liver and intestine via 
transcriptional regulation of xenobiotic-detoxifying enzymes and transporters, such as cytochrome 
P450 (CYP) and multiple drug resistance 1 (MDR1) [30].  
In this study, we determined whether fucoxanthin may overcome drug resistance through 
attenuation of rifampin-induced CYP3A4 and MDR1 gene expression by PXR-mediated pathways in 
HepG2 hepatoma cells. Mechanistically, we employed luciferase reporter gene assays to determine 
whether fucoxanthin attenuates the PXR-mediated CYP3A4 promoter activity. In addition, we used  
the mammalian two-hybrid assay to confirm the interaction between PXR and SRC-1, a main PXR  
co-activator. Our results may lead to the development of important new therapeutic and dietary 
approaches to reduce the frequency of undesirable drug interactions.  
2. Results  
2.1. Fucoxanthin Inhibits the Basal and Attenuated Rifampin-Induced CYP3A4 Enzyme Activity in 
HepG2 Cells 
To assess the effect of fucoxanthin on the basal and rifampin-induced CYP3A4 enzyme activity, 
HepG2 cells were treated with fucoxanthin (1–10 μM) alone or in the combination with human PXR 
(hPXR) inducer (20 μM rifampin) for 48 h. As shown in Figure 1A, treatment of HepG2 cells with 
fucoxanthin (1–10 μM) for 48 h significantly decreased the basal CYP3A4 enzyme activity (21% 
decrease, p < 0.05, at 10 μM fucoxanthin), as compared with that of untreated cells. Co-incubation of 
cells with fucoxanthin (1–10 μM) and rifampin (20 μM) significantly attenuated rifampin-induced 
CYP3A4 enzyme activity, and the inhibitory effect of fucoxanthin was concentration-dependent  
(26% decrease, p < 0.05, at 10 μM fucoxanthin) (Figure 1A). 
2.2. Fucoxanthin Inhibits the Basal and Attenuated Rifampin-Induced CYP3A4 mRNA Expression in 
HepG2 and LS174T Cells 
To elucidate whether the decreased CYP3A4 enzyme activity induced by fucoxanthin was due to 
the decreased mRNA expression, we used reverse transcriptase real-time PCR for CYP3A4 mRNA 
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assessment. We found that fucoxanthin (1–10 μM) significantly decreased the basal CYP3A4 mRNA 
expression in HepG2 and LS174T cells after incubation for 24 h (39%, p < 0.05 and 78%, p < 0.001, 
respectively, at 10 μM fucoxanthin), as compared with untreated cells (Figure 1B). Fucoxanthin  
(1–10 μM) also significantly decreased rifampin-induced CYP3A4 mRNA expression in HepG2  
cells and LS174T cells, with a 53% (p < 0.001) and a 65% (p < 0.001) inhibition, respectively, after 
incubation with 10 μM fucoxanthin for 24 h, as compared with rifampin-treated cells (Figure 1B). 
Figure 1. Effects of fucoxanthin (0–10 μM) alone or in combination with rifampin 
(20 μM) on CYP3A4 enzyme activity, CYP3A4 mRNA expression and CYP3A4 protein 
expression in human hepatoma HepG2 and colon adenocarcinoma LS174T cells:  
(A) CYP3A4 enzyme activity in HepG2 cells after incubation for 48 h; (B) CYP3A4 
mRNA expression in HepG2 cells and LS174T cells after incubation for 24 h;  
(C) CYP3A4 protein expression in HepG2 cells after incubation for 24 h; (D) CYP3A4 
protein expression in HepG2 cells after treatment with fucoxanthin in combination with 
rifampin. Values are means ± SD, n = 3; means without a common letter differ 
significantly (p < 0.05).  
(A) (B) 
(C) (D) 
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2.3. Fucoxanthin Inhibits the Basal and Attenuated Rifampin-Induced CYP3A4 Protein Expression in 
HepG2 Cells 
Western blotting was performed to evaluate the protein levels of CYP3A4. We found that fucoxanthin 
(1–10 μM) significantly decreased the basal CYP3A4 protein expression in a concentration-dependent 
manner (33%, p < 0.05, at 10 μM fucoxanthin, as compared with solvent control) (Figure 1C).  
Co-incubation of cells with fucoxanthin (1–10 μM) and rifampin (20 μM) significantly decreased 
rifampin-induced CYP3A4 protein expression (to the level of untreated cells), although the effect was 
not concentration-dependent (Figure 1D). These results are consistent with those of mRNA expression. 
2.4. Fucoxanthin Inhibits PXR-Mediated CYP3A4 Promoter Activity in HepG2 Cells 
Since hPXR is a dominant regulator of CYP3A4 expression, we assessed the inhibition of 
fucoxanthin on rifampin-induced hPXR transactivation activity on CYP3A4 promoter. As shown  
in Figure 2, 10 μM fucoxanthin significantly decreased the basal CYP3A4 promoter activity  
(70% decrease, as compared with the untreated group, p < 0.001). Treatment of HepG2 cells with 
fucoxanthin (1–10 μM) for 24 h also significantly attenuated the activation of PXR-mediated CYP3A4 
promoter induced by rifampin, and the effect of fucoxanthin was concentration-dependent, with 10 μM 
producing the greatest inhibitory effect (97% decrease, as compared with rifampin treatment alone,  
p < 0.001). 
Figure 2. Effects of fucoxanthin (0–10 μM) alone or fucoxanthin plus rifampin (20 μM) on 
human PXR-CYP3A4 promoter expression in HepG2 cells after incubation for 24 h. Values 
are means ± SD, n = 3; means without a common letter differ significantly (p < 0.05). 
 
2.5. Fucoxanthin Inhibits the Basal and Attenuated Rifampin-Induced MDR1 mRNA Expression in 
HepG2 and LS174T Cells 
We also evaluated the effect of fucoxanthin on mRNA expression of MDR1, another PXR-regulated 
gene. We found that fucoxanthin (1–10 μM) significantly decreased the basal expression of MDR1 
mRNA in HepG2 (Figure 3A) and LS174T (Figure 3B) cells after incubation for 24 h (55%, p < 0.01 
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and 59%, p < 0.001, respectively, at 10 μM fucoxanthin, as compared with the untreated group). 
Moreover, the induction of MDR1 mRNA expression by rifampin (20 μM) was attenuated by  
co-incubation with fucoxanthin (1–10 μM) for 24 h in both HepG2 and LS174T cells, with a 53%  
(p < 0.01) and a 63% (p < 0.001) inhibition, respectively, at 10 μM fucoxanthin, as compared with 
rifampin treatment alone.  
Figure 3. Effects of fucoxanthin (0–10 μM) on the multiple drug resistance 1 (MDR1) 
mRNA expression in HepG2 cells and LS174T cells after incubation for 24 h. Total DNA 
was isolated and the expression of indicated gene was determined by real-time PCR.  
(A) HepG2 cells; (B) LS174T cells. Values are means ± SD, n = 3; means without a common 
letter differ significantly (p < 0.05). 
 
(A) 
 
(B) 
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CYP3A4 transactivation. We found that fucoxanthin (1–10 μM) markedly attenuated [6-(4-chlorophenyl) 
imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-3,4-dichlorobenzyl) oxime], (CITCO)-induced CYP3A4 
promoter activation through CAR (88%, p < 0.001, as compared with CITCO treatment alone, at 
10 μM fucoxanthin) (Figure 4A). In addition, we found that fucoxanthin strongly attenuated rat-PXR 
mediated CYP3A4 promoter activity induced by 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN), 
whereas the effect of fucoxanthin at 10 μM was lower than for untreated cells (Figure 4B). The results 
indicate that fucoxanthin does not have a species-specific effect on human and rat PXR. In control 
experiments without overexpression of nuclear receptor, neither PXR nor CAR activity was increased 
or inhibited by fucoxanthin treatment.  
Figure 4. Effects of fucoxanthin (0–10 μM) alone or fucoxanthin plus rifampin (20 μM) on 
human constitutive androstane receptor (CAR) and mouse PXR-mediated CYP3A4 promoter 
expression in HepG2 cells after incubation for 24 h. (A) human CAR-mediated CYP3A4 
promoter expression; (B) mouse PXR-mediated CYP3A4 promoter expression. Values are 
means ± SD, n = 3; means without a common letter differ significantly (p < 0.05). 
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2.7. Fucoxanthin Disrupt the Interaction of PXR and Coactivator Interactions in HepG2 Cells 
We then evaluated that the effect of fucoxanthin on the interaction between PXR and coactivator 
(SRC-1) in HepG2 cells, as determined by the mammalian two-hybrid assay. As shown in Figure 5, 
fucoxanthin (1–10 μM) significantly decreased the interaction between PXR and SRC-1 in HepG2 cells 
after incubation for 24 h. In contrast, rifampin strongly promoted the specific interaction of PXR and 
SRC-1, whereas fucoxanthin significantly and concentration-dependently, attenuated rifampin-induced 
interaction between PXR and SRC-1, with an 80% inhibition (p < 0.001) at 10 μM fucoxanthin.  
The results indicate that fucoxanthin disrupts the interaction between PXR and SRC-1 both on the 
basal and rifampin-induced interaction, thereby potentially preventing transcriptional activation of  
PXR-regulated genes. 
Figure 5. Effects of fucoxanthin (0–10 μM) alone or fucoxanthin plus rifampin (20 μM) on 
PXR co-activator interactions in HepG2 cells after incubation for 24 h. Cells were transfected 
with a pBIND-SRC-1 and pCAT-PXR expression vector. Values are means ± SD, n = 3; 
means without a common letter differ significantly (p < 0.05). 
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coactivators have been shown to be important for nuclear receptor activation, including the SRC-1, 
transcriptional intermediary factor (TIF) 2, the activator of thyroid and retinoic acid receptor (ACTR),  
and peroxisome proliferator-activated receptor-binding protein (PBP) [31]. The binding of nuclear 
receptors to their ligands causes a conformational change, resulting in dissociation of corepressor 
proteins and recruitment of coactivator proteins, thereby potentially activating transcriptional levels of 
nuclear receptor-regulated genes [32]. In the present study, we found that fucoxanthin (1–10 μM) 
significantly and concentration-dependently attenuated rifampin-induced interaction between PXR  
and SRC-1, suggesting that fucoxanthin may inhibit PXR coactivator recruitment potential, thereby 
potentially preventing ligand-mediated PXR transcriptional activation of PXR-regulated genes. In the 
human CYP3A4 promoter, PXR can act as a heterodimer with RXRα, which then binds to an everted 
repeat, separated by 6 bp (ER6), located in the proximal promoter and a three-nucleotide spacer (DR3) 
as well as ER6 in the distal xenobiotic responsive enhancer module (XREM). This is located 
approximately 8 kbs upstream of the transcription start site [33,34]. We show here that fucoxanthin 
significantly attenuated rifampin-induced CYP3A4 and MDR1 expression through reduced  
PXR-mediated CYP3A4 promoter activity.  
The induction of both CYP450 and MDR1 genes at the transcriptional level is generally mediated by 
a PXR, CAR, glucocorticoid receptor (GR), and a vitamin D receptor (VDR) [35]. Among these 
receptors, PXR and CAR are members of the same nuclear receptor subfamily (NR1), sharing ~40% 
amino acid identity in their ligand binding domains (LBDs), which regulate an overlapping but not 
identical set of genes [36]. In the present study, we found that fucoxanthin (1–10 μM) strongly 
attenuated CAR-mediated CYP3A4 promoter activity induced by CITCO. Moreover, previous reports 
revealed that PXR and CAR exhibit promiscuous, low-affinity ligand binding characteristics [37]. 
Hence, CAR and PXR appear to share a similar mechanism, by recruiting SRC-1 in CYP3A4 
regulation [38]. Thus, PXR and CAR are considered the key transcriptional regulators of CYP3A4 and 
MDR1 [39]. 
PXR activation has been implicated in a number of clinically significant adverse drug–drug 
interactions and in increased cancer cell malignant phenotypes in response to PXR activation by 
drugs [20]. Hence, development of oral PXR antagonists with rapid absorption within the stomach and 
high hepatic extraction may be beneficial in preventing undesirable side effects in chronic patients who 
must take medications that are PXR activators. A lot of evidence exists to show that many PXR 
antagonists have been identified in vitro, such as the antineoplastic agent ecteinascidin-743 (ET-743), a 
marine-derived compound from the ascidian Ecetinascidia turbinanta [31], the antifungal agent 
ketoconazole (and related azoles) [40], the human HIV protease inhibitor, A-792611 [41], the 
phytoestrogen coumestrol [42], a topisomerase I inhibitor camptothecin [43], metformin [44] and the 
dietary isothiocyanate sulforaphane [45]. These are all functional inhibitors of PXR. In the present 
study, we found that fucoxanthin strongly attenuated rifampin-induced PXR activation, suggesting that 
fucoxanthin may be a PXR antagonist. 
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4. Experimental Section 
4.1. Chemicals and Reagents 
Dulbecco’s modified eagle medium (DMEM), fetal bovine serum (FBS), trypsin, penicillin, sodium 
pyruvate, and non-essential amino acids (NEAA) were purchased from GIBCO/BRL (Maryland, USA). 
Rifampin, 5-Pregnen-3β-ol-20-one-16α-carbonitrile (PCN), 6-(4-Chlorophenyl) imidazo[2,1-b][1,3] 
thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime (CITCO) were from Sigma-Aldrich (St. Louis, 
Missouri, USA) and dissolved in DMSO at appropriate concentrations. Anti-CYP3A4 goat polyclonal 
antibody and secondary antibody were from Santa Cruz (Santa Cruz, CA, USA). Fucoxanthin was 
extracted from Undaria pinnatifida and purified, as we reported previously [46]. The purity of 
fucoxanthin obtained as described above was 99.2%. The purified fucoxanthin was dissolved in 
ethanol to a final concentration of 10 mM as the stock solution. Before the experiment, fucoxanthin 
solutions were prepared freshly in a mixture of ethanol and FBS (1:9), as adopted from the preparation 
of lycopene solution [47].  
4.2. Cell Culture  
The human hepatoblastoma cell line HepG2 and human colon adenocarcinoma cell line LS174T 
were obtained from Food Industry Research and Development Institute (FIRDI, Taiwan) and maintained 
in DMEM supplemented with 10% fetal bovine serum without antibiotics, under 5% CO2 at 37 C.  
4.3. Plasmids Construction 
Plasmids pcDNA3-hPXR and pGL3B-CYP3A4 [(−444/+53) (−7836/−7208)] containing the  
full-length human PXR and CYP3A4 promoter reporter construct, respectively, have been reported 
previously [48]. A fragment encoding residue 595–800 of human SRC (GenBank accession number 
U90661) and full-length PXR was cloned into the pBIND-GAL4 and pACT-VP16 vector to become 
pBIND-SRC-1 and pACT-PXR, respectively, as described earlier [49]. A full-length human CAR 
cDNA (GenBank accession number NM_001077480) was purchased from Open Biosystems (Odyssey 
Drive Huntsville, Alabama, USA) and a full-length rat PXR (GenBank accession number 
NM_052980) was cloned from cDNA of rat liver. Both PCR products were amplified from cDNA 
using primers (for human CAR: forward primer, 5′-AAG GAT CCA CGT CAT GGC CAG TAG-3′; 
reverse primer, 5′-CCA ATC TAG AGC ATT TTC CCA CTC-3′; for rat PXR: forward primer,  
5′-GAT GGG ATC CTG GAG ATG AGA CCT GAG G-3′; reverse primer, 5′-CTC ATC TAG AGC 
CAC TCA GCC GTC CGT G-3′). The PCR product was digested with BamHI and XbaI, and 
restriction enzyme cut sites were introduced into the primers before the PCR. The cut fragment was 
cloned into the pcDNA3 vector with corresponding restriction enzyme sites to generate pcDNA3-hCAR 
and pcDNA3-rPXR, respectively. The reporter construct, pG5luc and internal control plasmid  
pRC-CMV-β-galactosidase, were purchased directly from Promega and Invitrogen (Groningen, The 
Netherlands), respectively. 
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4.4. Determination of CYP3A4 Enzymatic Activities Using P450-Glo™ Assay 
CYP3A4 enzyme activity was measured using P450-Glo™ assays (Promega, USA). Briefly, cells 
(3 × 105/mL) were subcultured into 12-well plates and were incubated with various concentrations of 
fucoxanthin. After incubation for 48 h, the medium was discarded, and the cells were rinsed twice 
using phosphate buffer saline. Fresh medium containing 50 μM luciferin-PFBE was added to cells and 
incubated for 3 h at 37 °C. Subsequently, 50 μL of the medium from each well was transferred to  
a 96-well opaque white luminometer plate, and 50 μL of luciferin detection reagent was added to 
initiate a luminescent reaction and then stabilized for 20 min. Luminescence was read using a 
luminometer, and luminescence signals were calculated by subtracting background luminescence 
values (no-cell control) from the values of the test compound and the blank (without the test compound). 
4.5. Real-Time Polymerase Chain Reaction of CYP3A4 and MDR1 
Total RNA in cell cultures was extracted with REzol reagent (PROtech Technologies, Inc.), and  
1 μg of total RNA was reverse-transcribed by using oligo-dT as a primer in 20 μL reverse-transcription 
solutions containing 1 μL reverse transcriptase (Promega, USA). Real-time PCR was performed with a 
Corbett instrument (Applied Biosystems) using SYBR Green Master Mix (ProTech, USA) according 
to the manufacturer’s instructions. In all real-time PCR experiments both a non-template control 
(NTC) and a standard curve were amplified as well. The RNA abundance was normalized to β-actin 
RNA in each sample. The primers and PCR condition used in this study are shown in Table 1. 
Table 1. Primer sequences used for real-time polymerase chain reaction. 
Gene 5′-3′ sequence PCR condition (45 cycles)
CYP3A4   
Forward 5′-GGGAAGCAGAGACAGGCAAG-3′ Denaturation 
Reverse 5′-GAGCGTTTCATTCACCACCA-3′ (30 s at 95 °C) 
MDR1   
Forward 5′-AAAAAGATCAACTCGTAGGAGTA-3′ Annealing 
Reverse 5′-GCACAAAATACACCAACAA-3′ (30 s at 60 °C) 
β-actin   
Forward 5′-GTGGGGCGCCCCAGGCACCA-3′ Extension 
Reverse 5′-CACCCCGCGGGGTCCGTGGT-3′ (30 s at 72 °C) 
4.6. Western Blotting 
Protein expression of CYP3A4 was measured by western blotting. In cell culture experiments, the 
medium was removed and cells were rinsed with phosphate buffered saline (PBS) twice. After the 
addition of 0.5 mL of cold radioimmunoprecipitation assay (RIPA) buffer and protease inhibitors, the 
cell lysates were then subjected to a centrifugation of 10,000 g for 30 min at 4 °C. Total protein (50 μg) 
from the supernatant was resolved on SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) 
membrane. After blocking with Tris-buffered saline (TBS) buffer (20 mmol/L Tris-HCl, 150 mmol/L 
NaCl, pH 7.4) containing 5% nonfat milk, the membrane was incubated with monoclonal antibody 
against human CYP3A4 followed by incubation with horseradish peroxidase-conjugated anti-goat IgG, 
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and then visualized using an ECL chemiluminescent detection kit (Amersham, Sweden). The relative 
density of the immunoreactive bands was quantitated by densitometry (Gel Pro Analyzer TM, 
version 3.0, Media Cybernetics, USA). 
4.7. Transient Transfection, CYP3A4 Reporter Assay, and Mammalian Two-Hybrid Assay 
HepG2 cells (1.8 × 104 cells/well) were plated in 96-microwell-white-plates (Nalge Nunc, 
Rochester, New York, USA) before transfection. For CYP3A4 reporter assay, plasmid DNA is 
introduced using the PolyJET™ (SignaGen Laboratories, Ijamsville, MD), whereas, for mammalian 
two-hybrid assays, we used Effectene® Transfection Reagent (Qiagen, Valencia, California, USA) 
according to the manufacturer instructions. For CYP3A4 reporter assays, 0.15 µg of CYP3A4 reporter 
construct, 0.02 µg of control β-galactosidase plasmid, and each 5 ng of pcDNA 3 vector or PXR 
expression plasmid were added per well, and the mixture was allowed to stand for 6–7 h. The cells 
were then exposed to rifampin/CITCO/PCN and/or fucoxanthin for 24 h before being lysed in situ with 
80 µL of Glo Lysis Buffer (Promega, Madison, Wisconsin, USA). Forty microliters of clear lysates 
were used for β-galactosidase assay. A 40-µL aliquot of each clear lysate was used for reporter assay, 
after which 40 µL ONE-Glo™ Luciferase Assay System (Promega, Madison, Wisconsin, USA) was 
added to the lysates. For mammalian two-hybrid assays, 0.1 µg of pG5luc reporter gene, 0.04 µg each 
of pBIND-GAL4 and pACT-VP16 constructs, and 0.02 µg of control β-galactosidase plasmid were 
added per well. After incubation for 6–7 h, the cells were exposed to rifampin and/or fucoxanthin, and 
after a further 24 h, the cells were lysed in situ with 90 µL of Cell Culture Lysis Reagent (Promega, 
USA). A 40-µL aliquot of each clear lysate was used for β-galactosidase assay, after which 80 µL 
Luciferase Assay System (Promega) was applied into the residual lysates. Luminescent signal was 
measured by using a luminescence multi-mode microplate reader (Synergy HT, BioTek Instruments Inc., 
Vermont, USA). Luciferase activities were normalized by the corresponding β-galactosidase activity. 
4.8. Statistical Analysis 
All experiments were repeated at least three times. Values are expressed as means ± SD and 
analyzed using one way ANOVA followed by LSD test for comparisons of group means. All statistical 
analyses were performed using SPSS for Windows, version 10 (SPSS, Inc.); a p value < 0.05 is 
considered statistically significant. 
5. Conclusions 
In conclusion, the present study demonstrates that fucoxanthin exhibits anti-drug-resistance potential 
and that the effect is likely to be associated with attenuated interaction between PXR and SRC-1, thereby 
potentially preventing activation of PXR-mediated CYP3A4 promoter expression. This leads to 
inhibition of PXR-regulated gene expression, including CYP3A4 and MDR1. The results suggest the 
potential use of fucoxanthin as an adjuvant to prevent drug-resistance in patients receiving chronic 
therapy with PXR agonists.  
  
Mar. Drugs 2012, 10  
 
 
254
Acknowledgments 
This study was supported by a grant (NSC-98-2320-B-005-005-MY3) from the National Science 
Council, Executive Yuan, Taiwan. 
References 
1. Maeda, H.; Hosokawa, M.; Sashima, T.; Takahashi, N.; Kawada, T.; Miyashita, K. Fucoxanthin 
and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int. J. Mol. 
Med. 2006, 18, 147–152. 
2. Nishino, H.; Tokuda, H.; Murakoshi, M.; Satomi, Y.; Masuda, M.; Onozuka, M.; Yamaguchi, S.; 
Takayasu, J.; Tsuruta, J.; Okuda, M.; Khachik, F.; Narisawa, T.; Takasuka, N.; Yano, M. Cancer 
prevention by natural carotenoids. Biofactors 2000, 13, 89–94. 
3. Shiratori, K.; Ohgami, K.; Ilieva, I.; Jin, X.H.; Koyama, Y.; Miyashita, K.; Yoshida, K.; Kase, S.; 
Ohno, S. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. 
Exp. Eye Res. 2005, 81, 422–428. 
4. Kotake-Nara, E.; Kushiro, M.; Zhang, H.; Sugawara, T.; Miyashita, K.; Nagao, A. Carotenoids 
affect proliferation of human prostate cancer cells. J. Nutr. 2001, 131, 3303–3306. 
5. Kotake-Nara, E.; Terasaki, M.; Nagao, A. Characterization of apoptosis induced by fucoxanthin in 
human promyelocytic leukemia cells. Biosci. Biotechnol. Biochem. 2005, 69, 224–227. 
6. Hosokawa, M.; Kudo, M.; Maeda, H.; Kohno, H.; Tanaka, T.; Miyashita, K. Fucoxanthin induces 
apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on 
colon cancer cells. Biochim. Biophys. Acta 2004, 1675, 113–119. 
7. Sugawara, T.; Baskaran, V.; Tsuzuki, W.; Nagao, A. Brown algae fucoxanthin is hydrolyzed to 
fucoxanthinol during absorption by caco-2 human intestinal cells and mice. J. Nutr. 2002, 132, 
946–951. 
8. Asai, A.; Sugawara, T.; Ono, H.; Nagao, A. Biotransformation of fucoxanthinol into 
amarouciaxanthin a in mice and HepG2 cells: Formation and cytotoxicity of fucoxanthin 
metabolites. Drug Metab. Dispos. 2004, 32, 205–211. 
9. Hashimoto, T.; Ozaki, Y.; Mizuno, M.; Yoshida, M.; Nishitani, Y.; Azuma, T.; Komoto, A.;  
Maoka, T.; Tanino, Y.; Kanazawa, K. Pharmacokinetics of fucoxanthinol in human plasma after 
the oral administration of kombu extract. Br. J. Nutr. 2011, 16, 1–4. 
10. Choi, B.H.; Kim, C.G.; Lim, Y.; Shin, S.Y.; Lee, Y.H. Curcumin down-regulates the  
multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 
2008, 259, 111–118. 
11. Chan, M.M.; Soprano, K.J.; Weinstein, K.; Fong, D. Epigallocatechin-3-gallate delivers hydrogen 
peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J. Cell. 
Physiol. 2006, 207, 389–396. 
12. Hwang, J.T.; Kwak, D.W.; Lin, S.K.; Kim, H.M.; Kim, Y.M.; Park, O.J. Resveratrol induces 
apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann. N. Y. 
Acad. Sci. 2007, 1095, 441–448. 
Mar. Drugs 2012, 10  
 
 
255
13. Pan, M.H.; Gao, J.H.; Lai, C.S.; Wang, Y.J.; Chen, W.M.; Lo, C.Y.; Wang, M.; Dushenkov, S.; 
Ho, C.T. Antitumor activity of 3,5,4′-trimethoxystilbene in COLO 205 cells and xenografts in 
SCID mice. Mol. Carcinog. 2008, 47, 184–196. 
14. Molnar, J.; Gyemant, N.; Mucsi, I.; Molnar, A.; Szabo, M.; Kortvelyesi, T.; Varga, A.; Molnár, P.; 
Tóth, G. Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids. 
In Vivo 2004, 18, 237–244. 
15. Guengerich, F.P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. 
Pharmacol. Toxicol. 1999, 39, 1–17. 
16. Moore, L.B.; Goodwin, B.; Jones, S.A.; Wisely, G.B.; Serabjit-Singh, C.J.; Willson, T.M.;  
Collins, J.L.; Kliewer, S.A. St. John’s wort induces hepatic drug metabolism through activation of 
the pregnane X receptor. Proc. Natl. Acad. Sci. USA 2000, 97, 7500–7502. 
17. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: From 
genomics to mechanism. Oncogene 2003, 22, 7468–7485. 
18. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; 
Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Overexpression of a transporter gene in a  
multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650–1654. 
19. Sharma, R.C.; Inoue, S.; Roitelman, J.; Schimke, R.T.; Simoni, R.D. Peptide transport by the 
multidrug resistance pump. J. Biol. Chem. 1992, 267, 5731–5734. 
20. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular 
targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 
15–21. 
21. Biswas, A.; Mani, S.; Redinbo, M.R.; Krasowski, M.D.; Li, H.; Ekins, S. Elucidating the “Jekyl 
and Hyde” nature of PXR: The case for discovering antagonists or Allosteric antagonists. Pharm. 
Res. 2009, 26, 1807–1815. 
22. Mukherjee, S.; Mani, S. Orphan nuclear receptors as targets for drug development. Pharm. Res. 
2010, 27, 1439–1468. 
23. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; 
Oliver, B.B.; Willson, T.M.; Zetterström, R.H.; Perlmann, T.; Lehmann, J.M. An orphan nuclear 
receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92, 73–82. 
24. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: A key regulator of 
xenobiotic metabolism. Endocr. Rev. 2002, 23, 687–702. 
25. Gollamudi, R.; Gupta, D.; Goel, S.; Mani, S. Novel orphan nuclear receptors-coregulator interactions 
controlling anti-cancer drug metabolism. Curr. Drug Metab. 2008, 9, 611–613.  
26. Wang, H.; Venkatesh, M.; Li, H.; Goetz, R.; Mukherjee, S.; Biswas, A.; Zhu, L.; Kaubisch, A.; 
Wang, L.; Pullman, J.; Whitney, K.; Kuro, M.; Roig, A.I.; Shay, J.W.; Mohammadi, M.; Mani, S. 
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and 
mice. J. Clin. Invest. 2011, 121, 3220–3232. 
27. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya, T.; Takanori, I.; Noriaki, O.; 
Bruce, B.; Hironobu, S. Expression of the steroid and xenobiotic receptor and its possible target 
gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 2006, 66, 
535–542. 
Mar. Drugs 2012, 10  
 
 
256
28. Chen, Y.; Nie, D. Pregnane X receptor and its potential role in drug resistance in cancer treatment. 
Recent Pat. Anticancer Drug Discov. 2009, 4, 19–27. 
29. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C.M.; Ong, E.S.;  
Evans, R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998, 12, 
3195–3205. 
30. Dussault, I.; Forman, B.M. The nuclear receptor PXR: A master regulator of “homeland” defense. 
Crit. Rev. Eukaryot. Gene Expr. 2002, 12, 53–64. 
31. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor SXR coordinately regulates 
drug metabolism and efflux. Nat. Med. 2001, 7, 584–590. 
32. Glass, C.K.; Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear 
receptors. Genes Dev. 2000, 14, 121–141. 
33. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; 
Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor 
defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA 1998, 95, 
12208–12213. 
34. Goodwin, B.; Hodgson, E.; Liddle, C. The orphan human pregnane X receptor mediates the 
transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. 
Pharmacol. 1999, 56, 1329–1339. 
35. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing 
enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 
2008, 9, 129–143. 
36. Moore, L.B.; Parks, D.J.; Jones, S.A.; Bledsoe, R.K.; Consler, T.G.; Stimmel, J.B.; Goodwin, B.; 
Liddle, C.; Blanchard, S.G.; Willson, T.M.; Collins, J.L.; Kliewer, S.A. Orphan nuclear receptors 
constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.  
J. Biol. Chem. 2000, 275, 15122–15127. 
37. Kliewer, S.A.; Willson, T.M. Regulation of xenobiotic and bile acid metabolism by the nuclear 
pregnane X receptor. J. Lipid Res. 2002, 43, 359–364. 
38. Auerbach, S.S.; Stoner, M.A.; Su, S.; Omiecinski, C.J. Retinoid X receptor-alpha-dependent 
transactivation by a naturally occurring structural variant of human constitutive androstane 
receptor (NR1I3). Mol. Pharmacol. 2005, 68, 1239–1253. 
39. Li, Y.; Wang, Q.; Yao, X. Induction of CYP3A4 and MDR1 gene expression by baicalin, 
baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and 
pregnane X receptor-mediated pathways. Eur. J. Pharmacol. 2010, 640, 46–54. 
40. Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M.R.; Teotico, D.G.; 
Locker, J.; Kalpana, G.V.; Mani, S. Inhibition of drug metabolism by blocking the activation of 
nuclear receptors by ketoconazole. Oncogene 2007, 26, 258–268. 
41. Healan-Greenberg, C.; Waring, J.F.; Kempf, D.J.; Blomme, E.A.; Tirona, R.G.; Kim, R.B.  
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human 
pregnane X receptor. Drug Metab. Dispos. 2007, 36, 500–507. 
  
Mar. Drugs 2012, 10  
 
 
257
42. Wang, H.; Li, H.; Moore, L.B.; Johnson, M.D.; Maglich, J.M.; Goodwin, B.; Parks, D.J.;  
Collins, J.L.; Willson, T.M.; Kalpana, G.V.; Venkatesh, M.; Xie, W.; Cho, S.Y.; Roboz, J.; 
Redinbo, M.; Moore, J.T.; Mani, S. The phytoestrogen coumestrol is a naturally occurring 
antagonist of the human pregnane X receptor. Mol. Endocrinol. 2008, 22, 838–857. 
43. Chen, Y.; Tang, Y.; Robbins, G.T.; Nie, D. Camptothecin attenuates cytochrome P450 3A4 
induction by blocking the activation of human pregnane X receptor. J. Pharmacol. Exp. Ther. 2010, 
334, 999–1008. 
44. Krausova, L.; Stejskalova, L.; Wang, H.; Vrzal, R.; Dvorak, Z.; Mani, S.; Pavek, P. Metformin 
suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem. 
Pharmcol. 2011, 82, 1771–1780. 
45. Zhou, C.; Poulton, E.J.; Grun, F.; Bammler, T.K.; Blumberg, B.; Thummel, K.E.; Eaton, D.L. The 
dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear 
receptor. Mol. Pharmacol. 2007, 71, 220–229. 
46. Liu, C.L.; Huang, Y.S.; Hosokawa, M.; Miyashita, K.; Hu, M.L. Inhibition of proliferation of a 
hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional 
intercellular communication. Chem. Biol. Interact. 2009, 182, 165–172. 
47. Lin, C.Y.; Huang, C.S.; Hu, M.L. The use of fetal bovine serum as delivery vehicle to improve 
the uptake and stability of lycopene in cell culture studies. Br. J. Nutr. 2007, 98, 226–232. 
48. Lim, Y.P.; Liu, C.H.; Shyu, L.J.; Huang, J.D. Functional characterization of a novel polymorphism 
of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics 2005, 15,  
337–441. 
49. Lim, Y.P.; Huang, J.D. Pregnane X receptor polymorphism affects CYP3A4 induction via a 
ligand-dependent interaction with steroid receptor coactivator-1. Pharmacogenet. Genomics 2007, 
17, 369–382. 
Samples Availability: Available from the authors. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
